EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY-NC 4.0

Improvement in Patient‐Reported Emotional Symptoms and Activity Limitations due to Hair Loss in Patients With Alopecia Areata Treated With Ritlecitinib: Additional Analyses From ALLEGRO ‐2b/3

Ernest H Law iD, Bintu Sherif iD, Arash Mostaghimi iD, Brett King iD, Rodney Sinclair iD, Natasha Mesinkovska iD, Kent A Hanson iD, Dane Korver iD, Costel Chirila iD

International Journal of Dermatology · 2026

DOI: 10.1111/ijd.70035 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Dermatology, 2026. Verfasst von Ernest H Law und 8 weiteren Autor:innen. Beteiligte Einrichtung: Pfizer, Inc., New York, New York, USA. Hauptthemen laut MEDLINE: Alopecia Areata. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Patients with alopecia areata (AA) in ALLEGRO‐2b/3 (NCT03732807) had clinically significant hair regrowth and patient‐reported improvements with ritlecitinib versus placebo, but patient‐reported improvements in AA Patient Priority Outcomes (AAPPO) emotional symptoms (ES) or activity limitations (AL) were not observed during the 24‐week placebo‐controlled phase. This study compared AAPPO scores between the 50‐mg ritlecitinib maintenance dose (+/− 200‐mg 4‐week loading dose) and subtherapeutic 10‐mg ritlecitinib through Week 48 of ALLEGRO‐2b/3.

Methods

Least squares mean (LSM) changes from baseline (CFBs) in domain scores were estimated for the full analysis population and for participants with baseline domain scores ≥ 1. Item‐level responses (scores < 2) were evaluated for participants with baseline item scores ≥ 2, since lower baseline item scores (measured on 5‐point response scales; range, 0–4) indicated less frequent/severe impacts from hair loss.

Results

There were 325 participants (200/50‐mg [ n = 132] and 50‐mg [ n = 130], combined and as subgroups; 10‐mg [ n = 63]). LSM CFBs in ES and AL domain scores generally improved through Week 48 for all 50‐mg groups, with significant differences versus 10‐mg starting at Week 34 for ES and Week 40 for AL. The proportion of responders for all ES and AL items generally increased through Week 48 for all 50‐mg groups. The largest improvements versus 10‐mg were for ES items 5 and 6 (self‐consciousness and embarrassment) and AL item 11 (interactions with others).

Conclusions

ALLEGRO‐2b/3 participants reported greater improvements in ES and AL due to hair loss by Week 48 with the 50‐mg ritlecitinib maintenance dose (+/− 200‐mg loading dose) versus subtherapeutic 10‐mg ritlecitinib.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alopecia AreataHumansMaleFemaleAdultPatient Reported Outcome MeasuresMiddle AgedEmotionsDouble-Blind MethodTreatment OutcomeHairYoung Adult

Stichwörter der Autor:innen

ALLEGRO‐2b/3activity limitationsalopecia areataalopecia areata patient priority outcomesemotional symptomshair losspatient‐reported outcomesritlecitinibtreatment

Autor:innen und Institutionen

  • Pfizer, Inc., New York, New York, USA.
  • RTI Health Solutions, North Carolina, USA.
  • Department of Dermatology, Brigham & Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Dermatology, Yale University, New Haven, Connecticut, USA.
  • Sinclair Dermatology, East Melbourne, Victoria, Australia.
  • Department of Dermatology, University of California, Irvine, California, USA.

ORCID-Profile: Ernest H Law, Bintu Sherif, Arash Mostaghimi, Brett King, Rodney Sinclair, Natasha Mesinkovska, Kent A Hanson, Dane Korver, Costel Chirila

Förderung

  • Pfizer

Zitieren

APA

Law, E. H., Sherif, B., Mostaghimi, A., King, B., Sinclair, R., Mesinkovska, N., Hanson, K. A., Korver, D., & Chirila, C. (2026). Improvement in Patient‐Reported Emotional Symptoms and Activity Limitations due to Hair Loss in Patients With Alopecia Areata Treated With Ritlecitinib: Additional Analyses From ALLEGRO ‐2b/3. International Journal of Dermatology. https://doi.org/10.1111/ijd.70035

Vancouver

Law EH, Sherif B, Mostaghimi A, King B, Sinclair R, Mesinkovska N, et al. Improvement in Patient‐Reported Emotional Symptoms and Activity Limitations due to Hair Loss in Patients With Alopecia Areata Treated With Ritlecitinib: Additional Analyses From ALLEGRO ‐2b/3. International Journal of Dermatology. 2026. doi:10.1111/ijd.70035

BibTeX
@article{Law2026,
  author = {Law, Ernest H and Sherif, Bintu and Mostaghimi, Arash and King, Brett and Sinclair, Rodney and Mesinkovska, Natasha and Hanson, Kent A and Korver, Dane and Chirila, Costel},
  title = {Improvement in Patient‐Reported Emotional Symptoms and Activity Limitations due to Hair Loss in Patients With Alopecia Areata Treated With Ritlecitinib: Additional Analyses From ALLEGRO ‐2b/3},
  journal = {International Journal of Dermatology},
  year = {2026},
  doi = {10.1111/ijd.70035}
}
Kostenlos starten →